c-fms expression is a molecular marker of human acute myeloid leukemias.
The c-fms protooncogene product was identified as the CSF-1 or M-CSF receptor, a polypeptide growth factor that plays a major role in myelomonocytic differentiation. This led us to look for expression of c-fms in fresh acute myeloid leukemia (AML) cells, using Northern blot analysis. c-fms expression was found in the leukemic cells of 28 AML patients, regardless of their stage of differentiation, which was assessed in the French-American-British (FAB) classification. However, the level of c-fms expression was especially high in AML of the M5 stage. High levels of expression were not accompanied by either amplification or rearrangements of the c-fms gene in AML cell DNAs. In contrast, c-fms expression was not found in acute lymphoid leukemias, whether of T or B origin. Thus, c-fms expression appears as a specific molecular marker of leukemogenesis in the myeloid lineage.
Dubreuil
P
P
INSERM, Marseille, France.
Torrès
H
H
Courcoul
M A
MA
Birg
F
F
Mannoni
P
P
D014408:Biomarkers, Tumor / Q000302:isolation & purification*; D002455:Cell Division; D002460:Cell Line; D005786:Gene Expression Regulation; D006412:Hematopoietic Stem Cells / Q000032:analysis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D011519:Proto-Oncogenes; D016186:Receptor, Macrophage Colony-Stimulating Factor
D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D016186:Receptor, Macrophage Colony-Stimulating Factor